Amplia Therapeutics Ltd (AU:ATX) — Market Cap & Net Worth
Market Cap & Net Worth: Amplia Therapeutics Ltd (ATX)
Amplia Therapeutics Ltd (AU:ATX) has a market capitalization of $41.77 Million (AU$59.03 Million) as of June 20, 2026. Listed on the AU stock exchange, this Australia-based company holds position #22600 globally and #822 in its home market, demonstrating a 4.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amplia Therapeutics Ltd's stock price AU$0.12 by its total outstanding shares 513312014 (513.31 Million). Review ATX total debt and obligations to assess the company's total debt and financial obligations.
Amplia Therapeutics Ltd Market Cap History: 2015 to 2026
Amplia Therapeutics Ltd's market capitalization history from 2015 to 2026. Data shows change from $623.83 Million to $41.77 Million (-21.98% CAGR).
Amplia Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amplia Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.40x
Amplia Therapeutics Ltd's market cap is 14.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $93.09 Million | $1.80 Million | -$7.08 Million | 51.77x | N/A |
| 2018 | $46.53 Million | $580.29K | -$4.30 Million | 80.18x | N/A |
| 2019 | $22.26 Million | $50.47K | -$1.87 Million | 441.10x | N/A |
| 2020 | $86.26 Million | $34.23K | -$2.22 Million | 2520.24x | N/A |
| 2021 | $59.93 Million | $1.53 Million | -$2.28 Million | 39.08x | N/A |
| 2022 | $29.06 Million | $1.98 Million | -$3.64 Million | 14.65x | N/A |
| 2023 | $29.06 Million | $1.19 Million | -$6.24 Million | 24.43x | N/A |
| 2024 | $32.32 Million | $4.45 Million | -$4.50 Million | 7.26x | N/A |
| 2025 | $54.48 Million | $3.78 Million | -$6.57 Million | 14.40x | N/A |
Competitor Companies of ATX by Market Capitalization
Companies near Amplia Therapeutics Ltd in the global market cap rankings as of June 20, 2026.
Key companies related to Amplia Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Amplia Therapeutics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Amplia Therapeutics Ltd's market cap moved from $623.83 Million to $ 41.77 Million, with a yearly change of -21.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$41.77 Million | -23.33% |
| 2025 | AU$54.48 Million | +68.54% |
| 2024 | AU$32.32 Million | +11.25% |
| 2023 | AU$29.06 Million | 0.00% |
| 2022 | AU$29.06 Million | -51.52% |
| 2021 | AU$59.93 Million | -30.53% |
| 2020 | AU$86.26 Million | +287.44% |
| 2019 | AU$22.26 Million | -52.15% |
| 2018 | AU$46.53 Million | -50.02% |
| 2017 | AU$93.09 Million | -97.44% |
| 2016 | AU$3.64 Billion | +483.49% |
| 2015 | AU$623.83 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 20th, 2026 the market cap of Amplia Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $41.77 Million USD |
| MoneyControl | $41.77 Million USD |
| MarketWatch | $41.77 Million USD |
| marketcap.company | $41.77 Million USD |
| Reuters | $41.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amplia Therapeutics Ltd
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develo… Read more